eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Randomized phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel in combination with carboplatin with or without concurrent and consolidation bevacizumab (NSC #704865, IND #7921) in the treatment of primary stage II, III or IV epithelial ovarian, peritoneal or fallopian tube cancer

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
  3. Intervention
  4. Intervention
  5. Additional Topic(s)
    Antineoplastic combined chemotherapy protocols
  6. Resource Description
    Giving bevacizumab together with combination chemotherapy may kill more tumor cells. It is not yet known whether giving paclitaxel once every three weeks is more effective than giving paclitaxel once a week. This randomized phase III clinical trial is studying two different dose schedules of paclitaxel to see how well they work in combination with carboplatin with or without bevacizumab in treating patients with stage III or stage IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer.
  7. Contact
    Berenberg, Jeffrey
  8. PI
    Berenberg, Jeffrey
  9. Topic
    ovarian cancer
  10. Study Population
    Females at least 18 years old, no more than 12 weeks since diagnostic/staging surgery, no previous cancer treatment that contraindicates study treatment, and no previous targeted therapy or hormone therapy for management of ovarian epithelial, fallopian tube, or primary peritoneal cancer.
  11. Website(s)
  12. Funded by
    Gynecologic Oncology Group
  13. Phase
    Phase 3 clinical trial
  14. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016